The following abstract presents results of a study conducted by a contract laboratory for the National Toxicology Program. The findings were not evaluated in accordance with the levels of evidence for reproductive or developmental criteria established by NTP in March 2009. The findings and conclusions for this study should not be construed to represent the views of NTP or the U.S. Government.
A Task la study in CD-1 mice on EGME at dose levels of 70, 250, and 700 mg/kg/day was conducted. The 250 and 700 mg/kg/day dosages induced testicular toxicity in males. The 700 mg/kg/day dosage produced some maternal toxicity (decreased body weight gain throughout the dosage period), and severe developmental toxicity was produced by both the 250 and 700 mg/kg/day dosages. These dosages of the test article increased resorption rates (total resorptions in the 700 mg/kg/day dosage group); the 250 mg/kg/day dosage decreased live litter size and pup viability, and produced gross external malformations. Hematological alterations, predominately thrombocytopenia and leukopenia, in both males and females were consistent with selective bone marrow toxicity at the 250 and 700 mg/kg/day doses. In males, the no-observable-adverse-effect-level for toxicity was 70 mg/kg/day. The 70 mg/kg/day dosage of EGME was the NOAEL for maternal toxicity and less than 70 mg/kg/day is the NOAEL for developmental toxicity.